All In Biotech

Drug Trial Radar · NCT05396885

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

A Phase II Study of CART-ddBCMA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

136

Actual

Start

Jul 15, 2022

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Arcellx, Inc.
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.

Conditions

  • Multiple Myeloma

Interventions

  • anitocabtagene-autoleucelBiological

    Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: 24 Months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Cancer Transplant Institute

    Scottsdale, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Moffitt Cancer Center

    Tampa, Florida

  • Northside Hospital

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah

  • University of Wisconsin Clinical Science Center

    Madison, Wisconsin

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.